Accelerate Diagnostics (AXDX) 10-Q10 May 182018 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 04, 2018
Document And Entity Information
Entity Registrant Name	Accelerate Diagnostics, Inc.
Entity Central Index Key	727,207
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		53,982,549
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 126,847	$ 28,513
Investments	66,754	80,648
Trade accounts receivable	1,065	1,946
Inventory	10,127	8,063
Prepaid expenses	1,538	850
Other current assets	804	468
Total current assets	207,135	120,488
Property and equipment, net	5,851	4,890
Intellectual property, net	129	134
Total assets	213,115	125,512
Current liabilities:
Accounts payable	2,758	2,080
Accrued liabilities	4,578	3,636
Deferred revenue and income	117	1,071
Total current liabilities	7,453	6,787
Other long term liabilities	25	21
Convertible notes	99,162	0
Total liabilities	106,640	6,808
Commitments and contingencies
Stockholders’ equity:
Preferred shares	0	0
Common stock	54	56
Contributed capital	414,262	360,620
Treasury Stock	(45,067)	0
Accumulated deficit	(262,833)	(241,972)
Accumulated other comprehensive loss	59	0
Total stockholders’ equity	106,475	118,704
Total liabilities and stockholders’ equity	$ 213,115	$ 125,512

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred Stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred Stock, shares authorized (shares)	5,000,000	5,000,000
Preferred Stock, shares outstanding (shares)	0	0
Common Stock, par value (usd per share)	$ 0.001	$ 0.001
Common Stock, shares authorized (shares)	75,000,000	75,000,000
Common Stock, shares issued (shares)	53,950,083	55,673,810
Common Stock, shares outstanding (shares)	53,950,083	55,673,810

CONDENSED CONSOLIDATEDSTATEMENT

CONDENSED CONSOLIDATEDSTATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Net sales	$ 801	$ 530
Cost of sales	492	26
Gross profit	309	504
Costs and expenses:
Research and development	6,782	4,288
Sales, general and administrative	14,353	10,526
Total costs and expenses	21,135	14,814
Loss from operations	(20,826)	(14,310)
Other income (expense):
Interest expense	(158)	0
Foreign currency exchange gain (loss)	55	(26)
Interest income	301	136
Total other income, net	198	110
Net loss before income taxes	(20,628)	(14,200)
Provision for income taxes	(184)	0
Net loss	$ (20,812)	$ (14,200)
Basic and diluted net loss per share (usd per share)	$ (0.37)	$ (0.27)
Weighted average shares outstanding (shares)	55,640	51,887
Other comprehensive loss:
Net loss	$ (20,812)	$ (14,200)
Net unrealized (loss) gain on available-for-sale investments	(53)	11
Foreign currency translation adjustment	112	56
Comprehensive loss	$ (20,753)	$ (14,133)

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (20,812)	$ (14,200)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	539	505
Amortization of intangible assets	5	3
Amortization of investment discount	19	121
Equity-based compensation	5,602	3,215
Non-cash interest expense	158	0
Loss on disposal of property and equipment	11	0
(Increase) decrease in assets:
Accounts receivable	881	(522)
Inventory	(1,917)	(4,155)
Prepaid expense and other	(653)	(457)
Other current assets	(336)	(280)
Increase (decrease) in liabilities:
Accounts payable	701	276
Accrued liabilities	733	(4)
Deferred revenue and income	(1,003)	29
Deferred compensation	4	0
Net cash used in operating activities	(16,068)	(15,469)
Cash flows from investing activities:
Purchases of equipment	(1,294)	(229)
Purchases of available-for-sale securities	(9,356)	(4,562)
Sales of available-for-sale securities	3,000	0
Maturity of available-for-sale securities	20,125	8,845
Net cash provided in investing activities	12,475	4,054
Cash flows from financing activities:
Issuance of common stock net of issuance costs	134	189
Exercise of options and warrants	1,112	1,844
Proceeds from issuance of convertible note	150,000	0
Prepayment of forward stock repurchase transaction	(45,069)	0
Payment of debt issuance costs	(4,330)	0
Net cash provided by financing activities	101,847	2,033
Effect of exchange rate on cash:	80	55
Increase (decrease) in cash and cash equivalents	98,334	(9,327)
Cash and cash equivalents, beginning of period	28,513	19,244
Cash and cash equivalents, end of period	$ 126,847	$ 9,917

Organization and Nature of Busi

Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies	NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or “the Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 , as filed with the SEC on March 1, 2018. The condensed consolidated balance sheet as of December 31, 2017 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2018 , or any future period. All amounts are rounded to the nearest thousand dollars unless otherwise indicated. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. Use of Estimates The Company’s consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of the Company’s consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventories, property and equipment, intangible assets, accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ materially from those estimates. Estimated Fair Value of Financial Instruments The Company follows ASC Topic 820, Fair Value Measurements and Disclosures which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories: • Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; • Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; • Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other liabilities approximate the related fair values due to the short-term maturities of these instruments. Cash and Cash Equivalents All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal. Investments The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of certificate of deposits, debt securities in U.S. government and agency securities, commercial paper, asset-backed securities and corporate notes and bonds. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment’s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income (loss) . Inventory The Company writes down its inventory for estimated obsolescence or in an amount equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand, market conditions and, where applicable, product expiration. Accounts Receivable Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable. Receivables are written off if reasonable collection efforts prove unsuccessful. The Company provides for allowances on a specific account basis. The Company has not included an allowance for doubtful accounts as of March 31, 2018 and December 31, 2017 , due to no circumstances arising that would indicate collection of any particular or grouping of customer accounts receivable is doubtful. Property and Equipment Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years . Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less. Property and equipment includes diagnostic instruments used for sales demonstrations and instruments under rental agreements. The Company retains title to the instruments under these arrangements. Long-lived Assets Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset. Warranty Reserve Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a 60 days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss. Warranty reserve activity for the three months ended March 31, 2018 and 2017 is as follows (in thousands): Three Months Ended March 31, March 31, 2018 2017 Beginning balance $ 192 $ 1 Provisions 121 30 Warranty expenses incurred (137 ) — Ending balance $ 176 $ 31 Convertible Notes The Company issued convertible notes that had conversion prices which resulted in an embedded beneficial conversion feature. The intrinsic value of the beneficial conversion feature was recorded as a debt discount with the corresponding amount to contributed capital. The debt discount is amortized to interest expense over the life of the convertible notes using the effective interest method. Revenue Recognition Effective January 1, 2018, the Company adopted the requirements of ASC 606, Revenue from Contracts with Customers , ("Topic 606") and recognizes revenue when control of the promised good or service is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues. We determine revenue recognition through the following steps: • Identification of the contract with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations • Recognition of revenue as we satisfy a performance obligation Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Service revenue is derived from the sale of extended service agreements which are generally non-cancelable. This revenue is recognized on a straight-line basis over the contract term beginning on the contractual date because the company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms. Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine standalone selling prices based on the price charged to customers for each individual performance obligation. We also provide instruments to customers under bundled rental agreements. Under these agreements, we install the instrument in the customer’s facility and provide service. The customer agrees to purchase consumable products at a stated price over the term of the agreement which is typically five years or less. Contracts sometimes have renewal clauses but such clauses do not provide for a bargain renewal option or penalize the customer if they do not renew. The instrument remains the Company’s property throughout the term of the agreement and there is no transfer of title upon expiration. Our payment terms vary by the type and location of our customer and the product or services offered and typically range between 30 and 60 days . Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were $0 for the quarter ended March 31, 2018 . The Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not complete as of January 1, 2018. We recorded a decrease to opening retained earnings and an increase in deferred revenue of $49,000 as of January 1, 2018 due to the cumulative impact of adopting Topic 606. The impact to revenues for the quarter ended March 31, 2018 was not material as a result of applying Topic 606. The reported results for 2017 and prior were prepared and are presented under the guidance of ASC 605, Revenue Recognition . Cost of Sales Cost of sales consists of raw materials, depreciation, direct labor and stock-based compensation expense, manufacturing overhead, facility costs and warranty costs. Shipping and Handling Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss. Leases The Company accounts for leases in accordance with ASC 840, Leases, which requires leases to be classified as either operating or capital leases. In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception. Other leases are classified as operating leases. Operating lease rent is recorded as an operating expense monthly. For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments. The asset is included with property and equipment on the condensed consolidated balance sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the statements of operations and comprehensive loss. For the liability, the amount due within the next year is recorded as a current liability and the amount due in more than a year is recorded as a long-term liability on the condensed consolidated balance sheet. Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the statements of operations and comprehensive loss. As of March 31, 2018 and December 31, 2017 the Company did not carry any capital leases. Equity-Based Compensation The Company awards stock options and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method). We account for forfeitures as they occur rather than on an estimated basis. The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. The Company records the fair value of Restricted Stock Units (“RSU's”) or Stock Grants (“SG's”) based on published closing market price on the day before the grant date. Income Taxes and Deferred Tax Assets Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment. The Company follows the provisions of ASC 740, Income Taxes , to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must determine it is more likely than not certain that its tax position will be sustained, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense. Foreign Currency Translation and Foreign Currency Transactions The Company follows ASC 830 Foreign Currency Matters , which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders’ equity. The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss. Earnings Per Share Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	3 Months Ended
Recently Issued Accounting Pronouncements	Mar. 31, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recently Issued Accounting Pronouncements	NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In March 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-05, Amendments Pursuant to SEC Staff Accounting Bulletin (“SAB”) No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “Tax Act”). In accordance with this guidance, the Company’s financial results reflect provisional amounts for those specific income tax effects of the Tax Act for which the accounting under ASC Topic 740 is incomplete but a reasonable estimate could be determined. During the three months ended March 31, 2018, the Company did not recognize any changes to the provisional amounts recorded in its 2017 Annual Report on Form 10-K in connection with the Tax Act, as the Company continues to collect the information necessary to complete those calculations. The accounting for the tax effects of the Tax Act will be completed in the second half of 2018. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220) - Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (AOCI), which allows a reclassification from accumulated other comprehensive income to retained earnings for tax effects resulting from the Act that the FASB refers to as having been stranded in AOCI. ASU 2018-02 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2018, with early adoption permitted. The Company is evaluating the impact of the adoption of ASU 2018-02 on the condensed consolidated financial statements, though its effects are not expected to be material. In March 2017, the FASB issued ASU 2017-08, Receivable-Nonrefundable Fees and Other Costs (Topic 310-20) Premium Amortization on Purchased Callable Debt Securities. This amendment shortens the amortization period for certain callable debt securities held at a premium. Specifically, the amendment requires premiums to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently assessing the impact this will have on our condensed consolidated financial statements. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740) Intra-Entity Transfers of Assets Other Than Inventory. This ASU is effective for periods after December 15, 2017 and eliminates the requirement that the Company recognize the income tax consequences of an intra-entity transfer of an asset upon transfer other than inventory, eliminating the current recognition requirement. For the Company, the ASU is effective for the 2018 annual reporting period including the interim period ended March 31, 2018. In adopting this ASU, the Company recorded no cumulative-effect adjustment to retained earnings at January 1, 2018. As the U.S. and the consolidated group are in tax losses, no prepaid tax has been recorded. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an “incurred loss” methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020, with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the condensed consolidated balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

FDA Clearance

FDA Clearance	3 Months Ended
FDA Clearance	Mar. 31, 2018
Research and Development [Abstract]
FDA Clearance	NOTE 3. FDA CLEARANCE On February 23, 2017, the U.S. Food and Drug Administration (“FDA”) granted Accelerate’s de novo request to market the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples. Due to various factors, the Company manufactured inventory in advance of regulatory approval (“pre-launch inventory”). On January 1, 2017, the regulatory review process had progressed to a point that objective and persuasive evidence of approval was sufficiently probable, and a future economic benefit existed. On January 1, 2017, the Company started capitalizing pre-launch inventory.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
Fair Value of Financial Instruments	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at March 31, 2018 and December 31, 2017 (in thousands): March 31, 2018 Quoted Prices Significant Significant Total Assets: Cash and cash equivalents Money market funds $ 21,918 $ — $ — $ 21,918 Investments: Certificates of deposit — 13,936 — 13,936 U.S. Treasury securities 18,863 — — 18,863 U.S. Agency securities — 6,941 — 6,941 Commercial paper — 2,791 — 2,791 Corporate notes and bonds — 24,223 — 24,223 Total investments 18,863 47,891 — 66,754 Total assets measured at fair value $ 40,781 $ 47,891 $ — $ 88,672 December 31, 2017 Quoted Prices Significant Significant Total Assets: Cash and cash equivalents: Money market funds $ 7,832 $ — $ — $ 7,832 Investments: Certificates of deposit — 13,441 — 13,441 U.S. Treasury securities 14,716 — — 14,716 U.S. Agency securities — 8,459 — 8,459 Commercial paper — 9,171 — 9,171 Asset-backed securities — 3,025 — 3,025 Corporate notes and bonds — 31,836 — 31,836 Total investments 14,716 65,932 — 80,648 Total assets measured at fair value $ 22,548 $ 65,932 $ — $ 88,480 Money market funds are included in cash and cash equivalents on the condensed consolidated balance sheet. Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds and U.S. Treasury securities as these specific assets are liquid. Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs. There were no transfers between levels during the three months ended March 31, 2018 .

Concentration of Credit Risk

Concentration of Credit Risk	3 Months Ended
Concentration of Credit Risk	Mar. 31, 2018
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	NOTE 5. CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers. The Company’s main financial institution for banking operations held 98% and 82% of the Company’s cash and cash equivalents as of March 31, 2018 and December 31, 2017 , respectively. The Company grants credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. Customers who represented 10% or more of the Company’s net accounts receivable balance as of March 31, 2018 and December 31, 2017 were as follows: March 31, December 31, 2018 2017 Customer A * 24% Customer B 18% * Customer C 15% * Customer D 11% * Customers who represented 10% or more of the Company’s total revenue for the three months ended March 31, 2018 and 2017 were as follows: March 31, March 31, 2018 2017 Customer A 11% 34% Customer B * 55% Customer C 26% * Customer D 12% * Customer E 14% * * Less than 10% for the period indicated

Investments

Investments	3 Months Ended
Investments	Mar. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Investments	NOTE 6. INVESTMENTS The following tables summarize the Company’s available-for-sale investments at March 31, 2018 and December 31, 2017 (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Certificates of deposit $ 13,936 $ — $ — $ 13,936 U.S. Treasury securities 18,963 — (100 ) 18,863 U.S. Agency securities 7,006 — (65 ) 6,941 Commercial paper 2,791 — — 2,791 Asset-backed securities — — — — Corporate notes and bonds 24,305 — (82 ) 24,223 Total $ 67,001 $ — $ (247 ) $ 66,754 Amortized Gross Gross Fair Value Certificates of deposit $ 13,441 $ — $ — $ 13,441 U.S. Treasury securities 14,787 — (71 ) 14,716 U.S. Agency securities 8,510 — (51 ) 8,459 Commercial paper 9,171 — — 9,171 Asset-backed securities 3,026 — (1 ) 3,025 Corporate notes and bonds 31,906 — (70 ) 31,836 Total $ 80,841 $ — $ (193 ) $ 80,648 The following table summarizes the maturities of the Company’s available-for-sale securities at March 31, 2018 and December 31, 2017 (in thousands): March 31, 2018 December 31, 2017 Amortized Fair Value Amortized Fair Value Due in less than 1 year $ 40,973 $ 40,864 $ 55,801 $ 55,735 Due in 1-5 years 26,028 25,890 25,040 24,913 Total $ 67,001 $ 66,754 $ 80,841 $ 80,648 Proceeds from sales of marketable securities (including principal paydowns) for the three months ended March 31, 2018 and 2017 , were $3.0 million and $0 , respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no realized gains from sales of marketable securities for the three months ended March 31, 2018 and 2017 . No balances were reclassified out of accumulated other comprehensive income (loss) for the three months ended March 31, 2018 and 2017 . No other-than-temporary impairments are recorded as no material investments had a fair value that remained less than its cost for more than twelve months as of those dates. The Company does not intend to sell investments and it is more likely than not that we will not be required to sell investments before recovering the amortized cost.

Inventory

Inventory	3 Months Ended
Inventory	Mar. 31, 2018
Inventory Disclosure [Abstract]
Inventory	NOTE 7. INVENTORY Inventories consisted of the following at March 31, 2018 and December 31, 2017 (in thousands): March 31, December 31, 2018 2017 Raw materials $ 4,854 $ 4,220 Work in process 808 377 Finished goods 4,465 3,466 Inventory, net $ 10,127 $ 8,063

Property and Equipment

Property and Equipment	3 Months Ended
Property and Equipment	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 8. PROPERTY AND EQUIPMENT Property and equipment consisted of the following at March 31, 2018 and December 31, 2017 (in thousands). March 31, December 31, 2018 2017 Computer equipment $ 2,776 $ 2,756 Technical equipment 3,585 3,348 Facilities 3,629 3,621 Instruments 2,359 1,400 Capital projects in progress 622 349 Total property and equipment $ 12,971 $ 11,474 Accumulated depreciation - other (7,120 ) (6,584 ) Property and equipment, net $ 5,851 $ 4,890 Depreciation expense (which includes amortization of capital lease assets) for the three months ended March 31, 2018 and 2017 was $539,000 and $505,000 , respectively.

License Agreements and Grants

License Agreements and Grants	3 Months Ended
License Agreements and Grants	Mar. 31, 2018
Research and Development [Abstract]
License Agreements and Grants	NOTE 9. LICENSE AGREEMENTS AND GRANTS National Institute of Health Grant In February 2015, the National Institute of Health awarded Denver Health and the Company a five -year, $5.0 million grant to develop a fast and reliable identification and categorical susceptibility test for carbepenem-resistant Enterobacteriaceae directly from whole blood. The cumulative award amount under these subawards is $885,000 . The amounts invoiced for the three months ended March 31, 2018 and 2017 were $60,000 and $3,000 , respectively. Arizona Commerce Authority In August 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority provided certain state and county sponsored incentives for the Company relocating its corporate headquarters to, and expanding its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority provided a total grant in the amount of $1.0 million (the “Grant”). The Grant was paid in four installments, upon the achievement of the following milestones: • Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below). • Milestone 2 – Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1). • Milestone 3 – Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2). • Milestone 4 – Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least $4.5 million . For purposes of the Grant Agreement, a “Qualified Job” was a job which was permanent, full-time, new to Arizona and for which the Company paid an average annual wage of at least $63,000 and included health insurance benefits, for which the Company paid at least 65% of the premiums. The Grant Agreement also contained other customary provisions, including representations, warranties and covenants of both parties. As of December 31, 2017 the full amount was collected and recorded in current deferred revenue and income. In January 2018, the full amount was recognized due to the economic development provisions of the grant being satisfied in full, and the “claw-back” provisions expiring. The $1.0 million was recognized as an offset to expense. Further details are included in Note 10, Deferred Revenue, Income and Remaining Performance Obligations .

Deferred Revenue, Income and Re

Deferred Revenue, Income and Remaining Performance Obligations	3 Months Ended
	Mar. 31, 2018
Deferred Revenue Disclosure [Abstract]
Deferred Revenue, Income and Remaining Performance Obligations	NOTE 10. DEFERRED REVENUE, INCOME AND REMAINING PERFORMANCE OBLIGATIONS Deferred revenue consists of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income. A summary of the balances as of March 31, 2018 and December 31, 2017 follows (in thousands): March 31, December 31, 2018 2017 Products and services not yet delivered $ 117 $ 71 Arizona Commerce Authority grant — 1,000 Deferred revenue and income $ 117 $ 1,071 In January 2018, $1.0 million in milestone payments from the Arizona Commerce Authority was recognized as an offset to expense. We also recognized $ 21,000 of revenues that were included in the contract liabilities balances at the beginning of the period. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods. Transaction Price Allocated to Remaining Performance Obligations As of March 31, 2018 , $ 737,000 of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to executed, extended-service contracts that begin as warranty periods expire. These contracts are typically four years and revenue is recognized on a straight-line basis over the contract term. As a practical expedient, the Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

Convertible Notes

Convertible Notes	3 Months Ended
Convertible Notes	Mar. 31, 2018
Debt Disclosure [Abstract]
Convertible Notes	NOTE 11. CONVERTIBLE NOTES On March 27, 2018 the Company issued $150.0 million aggregate principal amount of 2.50% Convertible Notes due 2023 (“Notes”). The Notes are the Company's senior unsecured obligations and mature on March 15, 2023 (Maturity Date), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Notes are convertible into cash, shares of the Company’s common stock, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.343 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company will pay interest on the Notes semi-annually in arrears on March 15 and September 15 of each year. The $150.0 million of proceeds received from the issuance of the Notes were allocated between long-term debt (the “liability component”) of $102.0 million and contributed capital (the “equity component”) of $48.0 million . The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Notes. The liability component will be accreted up to the face value of the Notes of $150.0 million , which will result in additional non-cash interest expense being recognized through the Notes’ Maturity Date. The effective interest rate on the Notes, including accretion of the Notes to par and debt issuance cost amortization, was 11.52% . The equity component will not be remeasured as long as it continues to meet the conditions for equity classification. The Company incurred approximately $4.3 million of issuance costs related to the issuance of the Notes, of which $2.9 million and $1.4 million were recorded to long-term debt and contributed capital, respectively. The $2.9 million of issuance costs recorded as long-term debt on the condensed consolidated balance sheet are being amortized over the five -year contractual term of the Notes using the effective interest method. The Notes include customary terms and covenants, including certain events of default after which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances: • if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018; • during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or • the occurrence of certain corporate events, such as a change of control, merger or liquidation. At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. As of March 31, 2018 , the outstanding principal on the Notes was $150.0 million , the unamortized debt discount was $48.0 million , the unamortized debt issuance cost was $2.9 million and the net carrying amount of the liability component was $99.2 million , which was recorded as convertible notes within the condensed consolidated balance sheet. For the three months ended March 31, 2018 , the Company recorded interest expense of $158,000 for contractual coupon interest, $6,000 for amortization of debt issuance costs, $100,000 for amortization of the debt discount, and $52,000 of accrued interest expense. As of March 31, 2018 no Notes were available for conversion. In connection with the debt issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500 . The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.

Earnings Per Share

Earnings Per Share	3 Months Ended
Earnings Per Share	Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 12. EARNINGS PER SHARE The Company’s net loss for the periods presented caused the inclusion of all outstanding warrants, restricted stock and options to purchase our common stock to be antidilutive. As of March 31, 2018 and December 31, 2017 , there were common stock options and restricted stock units exercisable for 8,099,816 and 7,352,281 shares of common stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.

Employee Equity-Based Compensat

Employee Equity-Based Compensation	3 Months Ended
Employee Equity-Based Compensation	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Equity-Based Compensation	NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION The following table summarizes option activity under all plans during the three -month period ended March 31, 2018 : Number of Shares Weighted Average Exercise Price per Share Options Outstanding January 1, 2018 7,328,131 $ 10.16 Granted 920,439 26.08 Forfeited (120,212 ) 9.25 Exercised (44,290 ) 18.31 Expired (352 ) 24.45 Options Outstanding March 31, 2018 8,083,716 11.94 The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded during the periods shown below: Three Months Ended March 31, March 31, 2018 2017 Expected term (in years) 6.11 6.19 Volatility 68 % 79 % Expected dividends — — Risk free interest rates 2.69 % 2.07 % Weighted average fair value $ 16.25 $ 16.84 The following table shows summary information for outstanding options and options that are exercisable (vested) as of March 31, 2018 : Options Outstanding Options Exercisable Number of options 8,083,716 5,667,598 Weighted average remaining contractual term (in years) 6.35 5.32 Weighted average exercise price $ 11.94 $ 7.86 Weighted average fair value $ 8.46 $ 5.59 Aggregate intrinsic value (in thousands) $ 93,003 $ 86,184 The following table summarizes restricted stock unit and restricted stock award activity during the three -month period ending March 31, 2018 : Number of Shares Weighted Average Grant Date Fair Value per Share Outstanding January 1, 2018 24,150 $ 26.45 Granted — — Forfeited — — Vested/released (8,050 ) 26.45 Outstanding March 31, 2018 16,100 26.45 Equity-based compensation is summarized below (in thousands): Three Months Ended March 31, March 31, 2018 2017 Cost of sales $ 46 $ — Research and development 1,612 726 Sales, general and administrative 3,944 2,489 Equity-based compensation expense $ 5,602 $ 3,215 As of March 31, 2018 , $451,000 and $81,000 of equity-based compensation expense was a component of capitalized inventory and property and equipment, respectively. As of March 31, 2018 , unrecognized equity-based compensation cost related to unvested stock options and unvested restricted stock units was $24.3 million and $ 135,000 , respectively. This is expected to be recognized over the years 2018 through 2023 .

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 14. INCOME TAXES For the three months ended March 31, 2018 , the Company recorded a provision for income taxes of approximately $184,000 , which primarily relates to profitable foreign jurisdictions without any net operating loss carryforwards. The Company’s tax expense for the three months ended March 31, 2018 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $20.6 million as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions. At March 31, 2018 , the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards. The Company provided a full valuation allowance against its deferred tax assets as future realization of such assets is not more likely than not to occur. We account for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes . For the three months ended March 31, 2018 , we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax position within the next 12 months. Tax Cuts and Jobs Act On December 22, 2017 , President Trump signed into law the Tax Cuts and Jobs Act . The Tax Act reduced the corporate tax rate from the maximum federal statutory rate of 35% to 21%. The Tax Act states that the 21% corporate tax rate is effective for tax years beginning on or after January 1, 2018 . The Company revalued its net deferred tax assets for U.S. federal purposes to 21% as of December 31, 2017 , with a corresponding adjustment to the valuation allowance. Therefore, the reduction in the U.S. corporate tax rate had no impact to the Company's earnings. In conjunction with the Tax Act, the SEC staff issued SAB 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has recognized the provisional tax impacts related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December 31, 2017 . The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act. Any subsequent determinations and adjustments will be recorded during the remainder of the year ended December 31, 2018 , as they are identified. The Tax Act subjects a U.S. shareholder to tax on Global intangible low-taxed income (“GILTI”) earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for GILTI, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. Given the complexity of the GILTI provisions, we are still evaluating the effects of the GILTI provisions and have not yet determined our accounting policy. At March 31, 2018 , because we are still evaluating the GILTI provisions and our analysis of future taxable income subject to GILTI, we have included GILTI related to current-year operations only in our estimated annual effective tax rate, with a corresponding adjustment to the valuation allowance, and have not provided additional GILTI on deferred items. At March 31, 2018 , the Company has not completed its accounting for all of the tax effects of the Tax Act and has not made any adjustments to the provisional amounts recorded at December 31, 2017 . The Company will continue to make and refine its calculations as additional analysis is completed. The Company’s estimates may also be affected as additional guidance is issued with regards to the Tax Act. These changes are not expected to be material to the Company’s financial statements since the effective tax rate impact will be offset by the corresponding adjustment in the valuation allowance.

Commitments

Commitments	3 Months Ended
Commitments	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 15. COMMITMENTS Leases The Company has entered into lease agreements, lease amendments, and lease extensions (“Lease Agreements”) for office, laboratory and manufacturing space located in Tucson, Arizona and Europe, the last of which expires in 2022. Total rent expense including common area charges was $342,000 and $293,000 for the three months ended March 31, 2018 and 2017 , respectively. Future minimum lease payments under these agreements are as follows (in thousands): Year ending December 31: 2018 $ 838 2019 204 2020 87 2021 46 2022 4 Thereafter — $ 1,179 Clinical Trial Agreements The Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs and then pay for work performed. These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation. Clinical trial master agreement expense was $9,000 for the three months ended March 31, 2017 , and no material expense was incurred for the three months ended March 31, 2018 . The expense incurred as part of the clinical trial is included in research and development on the Company's condensed consolidated statements of operations and comprehensive loss. Marketing Study and Contracted Research The Company has entered into marketing study agreements and contracted research agreements with research institutions and hospitals in which we typically pay a set amount for start-up costs and then pay for work performed. These agreements typically indemnify the sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation.

Industry and Geographic Informa

Industry and Geographic Information	3 Months Ended
Industry and Geographic Information	Mar. 31, 2018
Segment Reporting [Abstract]
Industry and Geographic Information	NOTE 16. INDUSTRY, GEOGRAPHIC AND REVENUE DISAGGREGATION The Company operates as one operating segment. Sales to customers outside the U.S. represented 26% , and 2% of total revenue for the three months ended March 31, 2018 and 2017 , respectively. As of March 31, 2018 and December 31, 2017 balances due from foreign customers, in U.S. dollars, were $553,000 and $1.0 million , respectively. Three Months Ended March 31, (in thousands) 2018 2017 Primary Geographic Markets Domestic $ 595 $ 518 Foreign 206 12 Net sales $ 801 $ 530 Line of Business Accelerate Pheno™ revenue $ 770 $ 504 Other revenue 31 26 Net sales $ 801 $ 530 Products and Services Products $ 796 $ 528 Services 5 2 Net sales $ 801 $ 530 Net sales includes $9,000 and $1,000 of lease income for the three months ended March 31, 2018 and 2017, respectively, which does not represent revenues recognized from contracts with customers. The following presents long-lived assets (excluding intangible assets) by geographic territory (in thousands): March 31, December 31, 2018 2017 Domestic $ 4,494 $ 3,779 Foreign 1,357 1,111 Property and equipment, net $ 5,851 $ 4,890

Related Party Transactions

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 17. RELATED PARTY TRANSACTIONS As part of the transaction discussed in Note 11, one member of the board of director's affiliated entities purchased an aggregate of $30 million of the Company's Notes. The affiliated entity is a Qualified Institutional Buyer which purchased and holds the Notes at March 31, 2018 .

Subsequent Events (Notes)

Subsequent Events (Notes)	3 Months Ended
Subsequent Events (Notes)	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 18. SUBSEQUENT EVENTS The Notes described in Note 11 provided for a 15% ( $22.5M ) overallotment option for 13 days following the execution of the purchase agreement. On April 6, 2018 this option was partially exercised and resulted in $21.5 million of additional proceeds. The issuance of the additional Notes will be allocated between long-term debt and contributed capital. This will result in an increase in long-term debt of $14.6 million and an increase in contributed capital of $6.9 million . The Company incurred approximately $645,000 of issuance costs related to the partial exercise, of which $439,000 and $206,000 will be recorded to long-term debt and contributed capital, respectively.

Organization and Nature of Bu24

Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 , as filed with the SEC on March 1, 2018. The condensed consolidated balance sheet as of December 31, 2017 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2018 , or any future period. All amounts are rounded to the nearest thousand dollars unless otherwise indicated.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of the Company’s consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventories, property and equipment, intangible assets, accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ materially from those estimates.
Estimated Fair Value of Financial Instruments	Estimated Fair Value of Financial Instruments The Company follows ASC Topic 820, Fair Value Measurements and Disclosures which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories: • Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; • Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; • Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other liabilities approximate the related fair values due to the short-term maturities of these instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.
Investments	Investments The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of certificate of deposits, debt securities in U.S. government and agency securities, commercial paper, asset-backed securities and corporate notes and bonds. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment’s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income (loss) .
Inventory	Inventory The Company writes down its inventory for estimated obsolescence or in an amount equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand, market conditions and, where applicable, product expiration.
Accounts Receivable	Accounts Receivable Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable. Receivables are written off if reasonable collection efforts prove unsuccessful. The Company provides for allowances on a specific account basis.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years . Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less. Property and equipment includes diagnostic instruments used for sales demonstrations and instruments under rental agreements. The Company retains title to the instruments under these arrangements.
Long-lived Assets	Long-lived Assets Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.
Warranty Reserve	Warranty Reserve Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a 60 days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.
Convertible Notes	Convertible Notes The Company issued convertible notes that had conversion prices which resulted in an embedded beneficial conversion feature. The intrinsic value of the beneficial conversion feature was recorded as a debt discount with the corresponding amount to contributed capital. The debt discount is amortized to interest expense over the life of the convertible notes using the effective interest method.
Revenue	Revenue Recognition Effective January 1, 2018, the Company adopted the requirements of ASC 606, Revenue from Contracts with Customers , ("Topic 606") and recognizes revenue when control of the promised good or service is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues. We determine revenue recognition through the following steps: • Identification of the contract with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations • Recognition of revenue as we satisfy a performance obligation Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Service revenue is derived from the sale of extended service agreements which are generally non-cancelable. This revenue is recognized on a straight-line basis over the contract term beginning on the contractual date because the company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms. Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine standalone selling prices based on the price charged to customers for each individual performance obligation. We also provide instruments to customers under bundled rental agreements. Under these agreements, we install the instrument in the customer’s facility and provide service. The customer agrees to purchase consumable products at a stated price over the term of the agreement which is typically five years or less. Contracts sometimes have renewal clauses but such clauses do not provide for a bargain renewal option or penalize the customer if they do not renew. The instrument remains the Company’s property throughout the term of the agreement and there is no transfer of title upon expiration. Our payment terms vary by the type and location of our customer and the product or services offered and typically range between 30 and 60 days . Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were $0 for the quarter ended March 31, 2018 . The Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not complete as of January 1, 2018. We recorded a decrease to opening retained earnings and an increase in deferred revenue of $49,000 as of January 1, 2018 due to the cumulative impact of adopting Topic 606. The impact to revenues for the quarter ended March 31, 2018 was not material as a result of applying Topic 606.
Cost of Sales	Cost of Sales Cost of sales consists of raw materials, depreciation, direct labor and stock-based compensation expense, manufacturing overhead, facility costs and warranty costs.
Shipping and Handling	Shipping and Handling Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.
Leases	Leases The Company accounts for leases in accordance with ASC 840, Leases, which requires leases to be classified as either operating or capital leases. In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception. Other leases are classified as operating leases. Operating lease rent is recorded as an operating expense monthly. For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments. The asset is included with property and equipment on the condensed consolidated balance sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the statements of operations and comprehensive loss. For the liability, the amount due within the next year is recorded as a current liability and the amount due in more than a year is recorded as a long-term liability on the condensed consolidated balance sheet. Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the statements of operations and comprehensive loss. As of March 31, 2018 and December 31, 2017 the Company did not carry any capital leases.
Equity-Based Compensation	Equity-Based Compensation The Company awards stock options and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method). We account for forfeitures as they occur rather than on an estimated basis. The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. The Company records the fair value of Restricted Stock Units (“RSU's”) or Stock Grants (“SG's”) based on published closing market price on the day before the grant date.
Income Taxes and Deferred Tax Assets	Income Taxes and Deferred Tax Assets Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment. The Company follows the provisions of ASC 740, Income Taxes , to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must determine it is more likely than not certain that its tax position will be sustained, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The Company follows ASC 830 Foreign Currency Matters , which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholders’ equity. The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.
Earnings Per Share	Earnings Per Share Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.
Recently Issued Accounting Pronouncements	In March 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-05, Amendments Pursuant to SEC Staff Accounting Bulletin (“SAB”) No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “Tax Act”). In accordance with this guidance, the Company’s financial results reflect provisional amounts for those specific income tax effects of the Tax Act for which the accounting under ASC Topic 740 is incomplete but a reasonable estimate could be determined. During the three months ended March 31, 2018, the Company did not recognize any changes to the provisional amounts recorded in its 2017 Annual Report on Form 10-K in connection with the Tax Act, as the Company continues to collect the information necessary to complete those calculations. The accounting for the tax effects of the Tax Act will be completed in the second half of 2018. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220) - Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (AOCI), which allows a reclassification from accumulated other comprehensive income to retained earnings for tax effects resulting from the Act that the FASB refers to as having been stranded in AOCI. ASU 2018-02 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2018, with early adoption permitted. The Company is evaluating the impact of the adoption of ASU 2018-02 on the condensed consolidated financial statements, though its effects are not expected to be material. In March 2017, the FASB issued ASU 2017-08, Receivable-Nonrefundable Fees and Other Costs (Topic 310-20) Premium Amortization on Purchased Callable Debt Securities. This amendment shortens the amortization period for certain callable debt securities held at a premium. Specifically, the amendment requires premiums to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently assessing the impact this will have on our condensed consolidated financial statements. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740) Intra-Entity Transfers of Assets Other Than Inventory. This ASU is effective for periods after December 15, 2017 and eliminates the requirement that the Company recognize the income tax consequences of an intra-entity transfer of an asset upon transfer other than inventory, eliminating the current recognition requirement. For the Company, the ASU is effective for the 2018 annual reporting period including the interim period ended March 31, 2018. In adopting this ASU, the Company recorded no cumulative-effect adjustment to retained earnings at January 1, 2018. As the U.S. and the consolidated group are in tax losses, no prepaid tax has been recorded. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an “incurred loss” methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020, with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the condensed consolidated balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

Organization and Nature of Bu25

Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of Product Warranty Reserve Activity	Warranty reserve activity for the three months ended March 31, 2018 and 2017 is as follows (in thousands): Three Months Ended March 31, March 31, 2018 2017 Beginning balance $ 192 $ 1 Provisions 121 30 Warranty expenses incurred (137 ) — Ending balance $ 176 $ 31

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	3 Months Ended
Fair Value of Financial Instruments (Tables)	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurement	The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at March 31, 2018 and December 31, 2017 (in thousands): March 31, 2018 Quoted Prices Significant Significant Total Assets: Cash and cash equivalents Money market funds $ 21,918 $ — $ — $ 21,918 Investments: Certificates of deposit — 13,936 — 13,936 U.S. Treasury securities 18,863 — — 18,863 U.S. Agency securities — 6,941 — 6,941 Commercial paper — 2,791 — 2,791 Corporate notes and bonds — 24,223 — 24,223 Total investments 18,863 47,891 — 66,754 Total assets measured at fair value $ 40,781 $ 47,891 $ — $ 88,672 December 31, 2017 Quoted Prices Significant Significant Total Assets: Cash and cash equivalents: Money market funds $ 7,832 $ — $ — $ 7,832 Investments: Certificates of deposit — 13,441 — 13,441 U.S. Treasury securities 14,716 — — 14,716 U.S. Agency securities — 8,459 — 8,459 Commercial paper — 9,171 — 9,171 Asset-backed securities — 3,025 — 3,025 Corporate notes and bonds — 31,836 — 31,836 Total investments 14,716 65,932 — 80,648 Total assets measured at fair value $ 22,548 $ 65,932 $ — $ 88,480

Concentration of Credit Risk (T

Concentration of Credit Risk (Tables)	3 Months Ended
Concentration of Credit Risk (Tables)	Mar. 31, 2018
Risks and Uncertainties [Abstract]
Schedule of Customer Concentration	Customers who represented 10% or more of the Company’s net accounts receivable balance as of March 31, 2018 and December 31, 2017 were as follows: March 31, December 31, 2018 2017 Customer A * 24% Customer B 18% * Customer C 15% * Customer D 11% * Customers who represented 10% or more of the Company’s total revenue for the three months ended March 31, 2018 and 2017 were as follows: March 31, March 31, 2018 2017 Customer A 11% 34% Customer B * 55% Customer C 26% * Customer D 12% * Customer E 14% * * Less than 10% for the period indicated

Investments (Tables)

Investments (Tables)	3 Months Ended
Investments (Tables)	Mar. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-Sale Investments	The following tables summarize the Company’s available-for-sale investments at March 31, 2018 and December 31, 2017 (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Certificates of deposit $ 13,936 $ — $ — $ 13,936 U.S. Treasury securities 18,963 — (100 ) 18,863 U.S. Agency securities 7,006 — (65 ) 6,941 Commercial paper 2,791 — — 2,791 Asset-backed securities — — — — Corporate notes and bonds 24,305 — (82 ) 24,223 Total $ 67,001 $ — $ (247 ) $ 66,754 Amortized Gross Gross Fair Value Certificates of deposit $ 13,441 $ — $ — $ 13,441 U.S. Treasury securities 14,787 — (71 ) 14,716 U.S. Agency securities 8,510 — (51 ) 8,459 Commercial paper 9,171 — — 9,171 Asset-backed securities 3,026 — (1 ) 3,025 Corporate notes and bonds 31,906 — (70 ) 31,836 Total $ 80,841 $ — $ (193 ) $ 80,648
Schedule of Available-For-Sale Investment Maturities	The following table summarizes the maturities of the Company’s available-for-sale securities at March 31, 2018 and December 31, 2017 (in thousands): March 31, 2018 December 31, 2017 Amortized Fair Value Amortized Fair Value Due in less than 1 year $ 40,973 $ 40,864 $ 55,801 $ 55,735 Due in 1-5 years 26,028 25,890 25,040 24,913 Total $ 67,001 $ 66,754 $ 80,841 $ 80,648

Inventory (Tables)

Inventory (Tables)	3 Months Ended
Inventory (Tables)	Mar. 31, 2018
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following at March 31, 2018 and December 31, 2017 (in thousands): March 31, December 31, 2018 2017 Raw materials $ 4,854 $ 4,220 Work in process 808 377 Finished goods 4,465 3,466 Inventory, net $ 10,127 $ 8,063

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
Property and Equipment (Tables)	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment consisted of the following at March 31, 2018 and December 31, 2017 (in thousands). March 31, December 31, 2018 2017 Computer equipment $ 2,776 $ 2,756 Technical equipment 3,585 3,348 Facilities 3,629 3,621 Instruments 2,359 1,400 Capital projects in progress 622 349 Total property and equipment $ 12,971 $ 11,474 Accumulated depreciation - other (7,120 ) (6,584 ) Property and equipment, net $ 5,851 $ 4,890

Deferred Revenue, Income and 31

Deferred Revenue, Income and Remaining Performance Obligations (Tables)	3 Months Ended
	Mar. 31, 2018
Deferred Revenue Disclosure [Abstract]
Deferred Revenue and Income Summary	A summary of the balances as of March 31, 2018 and December 31, 2017 follows (in thousands): March 31, December 31, 2018 2017 Products and services not yet delivered $ 117 $ 71 Arizona Commerce Authority grant — 1,000 Deferred revenue and income $ 117 $ 1,071

Employee Equity-Based Compens32

Employee Equity-Based Compensation (Tables)	3 Months Ended
Employee Equity-Based Compensation (Tables)	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Activity	The following table summarizes option activity under all plans during the three -month period ended March 31, 2018 : Number of Shares Weighted Average Exercise Price per Share Options Outstanding January 1, 2018 7,328,131 $ 10.16 Granted 920,439 26.08 Forfeited (120,212 ) 9.25 Exercised (44,290 ) 18.31 Expired (352 ) 24.45 Options Outstanding March 31, 2018 8,083,716 11.94
Inputs to Calculate Estimated Fair Value of Options Awarded	The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded during the periods shown below: Three Months Ended March 31, March 31, 2018 2017 Expected term (in years) 6.11 6.19 Volatility 68 % 79 % Expected dividends — — Risk free interest rates 2.69 % 2.07 % Weighted average fair value $ 16.25 $ 16.84
Stock Option Supplemental Information	The following table shows summary information for outstanding options and options that are exercisable (vested) as of March 31, 2018 : Options Outstanding Options Exercisable Number of options 8,083,716 5,667,598 Weighted average remaining contractual term (in years) 6.35 5.32 Weighted average exercise price $ 11.94 $ 7.86 Weighted average fair value $ 8.46 $ 5.59 Aggregate intrinsic value (in thousands) $ 93,003 $ 86,184
Restricted Stock Unit (RSU) Activity	The following table summarizes restricted stock unit and restricted stock award activity during the three -month period ending March 31, 2018 : Number of Shares Weighted Average Grant Date Fair Value per Share Outstanding January 1, 2018 24,150 $ 26.45 Granted — — Forfeited — — Vested/released (8,050 ) 26.45 Outstanding March 31, 2018 16,100 26.45
Equity-Based Compensation Expenses	Equity-based compensation is summarized below (in thousands): Three Months Ended March 31, March 31, 2018 2017 Cost of sales $ 46 $ — Research and development 1,612 726 Sales, general and administrative 3,944 2,489 Equity-based compensation expense $ 5,602 $ 3,215

Commitments (Tables)

Commitments (Tables)	3 Months Ended
Commitments (Tables)	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating Leases Obligations	Future minimum lease payments under these agreements are as follows (in thousands): Year ending December 31: 2018 $ 838 2019 204 2020 87 2021 46 2022 4 Thereafter — $ 1,179

Industry and Geographic Infor34

Industry and Geographic Information (Tables)	3 Months Ended
Industry and Geographic Information (Tables)	Mar. 31, 2018
Segment Reporting [Abstract]
Disaggregation of Revenue	Three Months Ended March 31, (in thousands) 2018 2017 Primary Geographic Markets Domestic $ 595 $ 518 Foreign 206 12 Net sales $ 801 $ 530 Line of Business Accelerate Pheno™ revenue $ 770 $ 504 Other revenue 31 26 Net sales $ 801 $ 530 Products and Services Products $ 796 $ 528 Services 5 2 Net sales $ 801 $ 530
Long-lived Assets by Geographic Territory	The following presents long-lived assets (excluding intangible assets) by geographic territory (in thousands): March 31, December 31, 2018 2017 Domestic $ 4,494 $ 3,779 Foreign 1,357 1,111 Property and equipment, net $ 5,851 $ 4,890

- Narrative (Details)

- Narrative (Details) - USD ($)	3 Months Ended
- Narrative (Details) - USD ($)	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Instrument warranty term	1 year
Kits and accessories warranty term	60 days
Contract asset balance	$ 0	$ 0
Decrease to opening retained earnings	$ 262,833,000		$ 241,972,000
Cumulative impact of adopting Topic 606 \| Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Decrease to opening retained earnings		$ 49,000
Minimum
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Payment terms	30 days
Estimated useful life of assets	1 year
Maximum
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Payment terms	60 days
Estimated useful life of assets	7 years

Organization and Nature of Bu36

Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 192	$ 1
Provisions	121	30
Warranty expenses incurred	(137)	0
Ending balance	$ 176	$ 31

Fair Value of Financial Instr37

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$ 66,754	$ 80,648
Fair value on a recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	66,754	80,648
Total assets measured at fair value	88,672	88,480
Fair value on a recurring basis \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	18,863	14,716
Total assets measured at fair value	40,781	22,548
Fair value on a recurring basis \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	47,891	65,932
Total assets measured at fair value	47,891	65,932
Fair value on a recurring basis \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Total assets measured at fair value	0	0
Fair value on a recurring basis \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	13,936	13,441
Fair value on a recurring basis \| Certificates of deposit \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| Certificates of deposit \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	13,936	13,441
Fair value on a recurring basis \| Certificates of deposit \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	18,863	14,716
Fair value on a recurring basis \| U.S. Treasury securities \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	18,863	14,716
Fair value on a recurring basis \| U.S. Treasury securities \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| U.S. Treasury securities \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| U.S. Agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	6,941	8,459
Fair value on a recurring basis \| U.S. Agency securities \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| U.S. Agency securities \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	6,941	8,459
Fair value on a recurring basis \| U.S. Agency securities \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	2,791	9,171
Fair value on a recurring basis \| Commercial paper \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| Commercial paper \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	2,791	9,171
Fair value on a recurring basis \| Commercial paper \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		3,025
Fair value on a recurring basis \| Asset-backed securities \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Fair value on a recurring basis \| Asset-backed securities \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		3,025
Fair value on a recurring basis \| Asset-backed securities \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Fair value on a recurring basis \| Corporate notes and bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	24,223	31,836
Fair value on a recurring basis \| Corporate notes and bonds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| Corporate notes and bonds \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	24,223	31,836
Fair value on a recurring basis \| Corporate notes and bonds \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Fair value on a recurring basis \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	21,918	7,832
Fair value on a recurring basis \| Money market funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	21,918	7,832
Fair value on a recurring basis \| Money market funds \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Fair value on a recurring basis \| Money market funds \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 0	$ 0

Concentration of Credit Risk (D

Concentration of Credit Risk (Details)	3 Months Ended		12 Months Ended
Concentration of Credit Risk (Details)	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Cash and cash equivalents \| Concentration of credit risk
Concentration Risk [Line Items]
Risk concentration	98.00%		82.00%
Net accounts receivable \| Customer concentration \| Customer A
Concentration Risk [Line Items]
Risk concentration			24.00%
Net accounts receivable \| Customer concentration \| Customer B
Concentration Risk [Line Items]
Risk concentration	18.00%
Net accounts receivable \| Customer concentration \| Customer C
Concentration Risk [Line Items]
Risk concentration	15.00%
Net accounts receivable \| Customer concentration \| Customer D
Concentration Risk [Line Items]
Risk concentration	11.00%
Total revenue \| Customer concentration \| Customer A
Concentration Risk [Line Items]
Risk concentration	11.00%	34.00%
Total revenue \| Customer concentration \| Customer B
Concentration Risk [Line Items]
Risk concentration		55.00%
Total revenue \| Customer concentration \| Customer C
Concentration Risk [Line Items]
Risk concentration	26.00%
Total revenue \| Customer concentration \| Customer D
Concentration Risk [Line Items]
Risk concentration	12.00%
Total revenue \| Customer concentration \| Customer E
Concentration Risk [Line Items]
Risk concentration	14.00%

Investments - Schedule of Avail

Investments - Schedule of Available-for-sale Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Investment [Line Items]
Amortized Cost	$ 67,001	$ 80,841
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(247)	(193)
Fair Value	66,754	80,648
Certificates of deposit
Investment [Line Items]
Amortized Cost	13,936	13,441
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	13,936	13,441
U.S. Treasury securities
Investment [Line Items]
Amortized Cost	18,963	14,787
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(100)	(71)
Fair Value	18,863	14,716
U.S. Agency securities
Investment [Line Items]
Amortized Cost	7,006	8,510
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(65)	(51)
Fair Value	6,941	8,459
Commercial paper
Investment [Line Items]
Amortized Cost	2,791	9,171
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	2,791	9,171
Asset-backed securities
Investment [Line Items]
Amortized Cost	0	3,026
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	(1)
Fair Value	0	3,025
Corporate notes and bonds
Investment [Line Items]
Amortized Cost	24,305	31,906
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(82)	(70)
Fair Value	$ 24,223	$ 31,836

Investments - Schedule of Ava40

Investments - Schedule of Available-for-Sale Investment Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Amortized Cost
Due in less than 1 year	$ 40,973	$ 55,801
Due in 1-5 years	26,028	25,040
Total	67,001	80,841
Fair Value
Due in less than 1 year	40,864	55,735
Due in 1-5 years	25,890	24,913
Total	$ 66,754	$ 80,648

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($)	3 Months Ended
Investments - Narrative (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Proceeds from sales of marketable securities	$ 3,000,000	$ 0
Gross realized gains or losses from sales of marketable securities	$ 0	$ 0

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 4,854	$ 4,220
Work in process	808	377
Finished goods	4,465	3,466
Inventory, net	$ 10,127	$ 8,063

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 12,971		$ 11,474
Accumulated depreciation - other	(7,120)		(6,584)
Property and equipment, net	5,851		4,890
Depreciation	539	$ 505
Computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	2,776		2,756
Technical equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	3,585		3,348
Facilities
Property, Plant and Equipment [Line Items]
Total property and equipment	3,629		3,621
Instruments
Property, Plant and Equipment [Line Items]
Total property and equipment	2,359		1,400
Capital projects in progress
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 622		$ 349

License Agreements and Grants -

License Agreements and Grants - National Institute of Health Grant (Details) - National Institute of Health Grant - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		35 Months Ended
	Feb. 28, 2015	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Proposed Period	5 years
Total grant funding	$ 5,000	$ 60	$ 3
Research and Development Arrangement, Contract to Perform for Others, Invoiced				$ 885

License Agreements and Grants45

License Agreements and Grants - Arizona Commerce Authority and R&D Refundable Tax Credit Program (Details)	1 Months Ended
	Jan. 31, 2018USD ($)	Aug. 31, 2012USD ($)jobmilestone
Research and Development [Abstract]
Arizona Commerce Authority grant \| $		$ 1,000,000
Number of installments \| milestone		4
Qualified jobs created, milestone 1 \| job		15
Qualified jobs created, milestone 2 \| job		30
Qualified jobs created, milestone 3 \| job		40
Qualified jobs created, milestone 4 \| job		65
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized \| $	$ 1,000,000
Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Capital investment milestone \| $		$ 4,500,000
Grant related minimum annual wages \| $		$ 63,000
Percent of company paid premiums		65.00%

Deferred Revenue, Income and 46

Deferred Revenue, Income and Remaining Performance Obligations (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Deferred Revenue Disclosure [Abstract]
Products and services not yet delivered		$ 117	$ 71
Arizona Commerce Authority grant		0	1,000
Deferred revenue and income		117	$ 1,071
Revenue recognized	$ 1,000
Revenues recognized included in contract liabilities balances		21
Revenue expected to be recognized from remaining performance obligations		$ 737
Contact period		4 years

Convertible Notes (Details)

Convertible Notes (Details)	Mar. 27, 2018USD ($)day$ / sharesshares	Mar. 31, 2018USD ($)
Debt Instrument [Line Items]
Conversion ratio	0.032343
Stock price conversion threshold, percentage	130.00%
Consecutive trading days \| day	20
Threshold trading days	30
Trading price threshold, percentage	98.00%
Repurchase principal balance, percent	100.00%
Net carrying amount		$ 99,200,000
Interest expense		158,000
Amortization of debt issuance costs		6,000
Amortization of the debt discount		100,000
Interest Payable		52,000
Net proceeds from notes to fund Prepaid Forward	$ 45,100,000
Aggregate number of shares \| shares	1,858,500
Unsecured obligations \| 2.50% Convertible notes due 2023
Debt Instrument [Line Items]
Aggregate principal amount	$ 150,000,000
Interest rate	2.50%
Conversion multiple	$ 1,000
Initial conversion price (usd per share) \| $ / shares	$ 30.92
Proceeds received	$ 150,000,000
Long-term debt	102,000,000
Equity component	$ 48,000,000
Effective interest rate	11.52%
Debt issuance costs	$ 4,300,000
Contractual term	5 years
Unamortized debt discount		$ 48,000,000
Unsecured obligations \| 2.50% Convertible notes due 2023 \| Long-term debt
Debt Instrument [Line Items]
Debt issuance costs	$ 2,900,000
Unamortized debt issuance cost	2,900,000
Unsecured obligations \| 2.50% Convertible notes due 2023 \| Additional paid-in capital
Debt Instrument [Line Items]
Debt issuance costs	$ 1,400,000

Earnings Per Share (Details)

Earnings Per Share (Details) - shares	3 Months Ended	12 Months Ended
Earnings Per Share (Details) - shares	Mar. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Antidilutive common stock instruments outstanding (shares)	8,099,816	7,352,281

Employee Equity-Based Compens49

Employee Equity-Based Compensation - Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Number of Shares
Outstanding, beginning balance (shares) \| shares	7,328,131
Granted (shares) \| shares	920,439
Forfeited (shares) \| shares	(120,212)
Exercised (shares) \| shares	(44,290)
Expired (shares) \| shares	(352)
Outstanding, ending balance (shares) \| shares	8,083,716
Weighted Average Exercise Price per Share
Outstanding, beginning balance (dollars per share) \| $ / shares	$ 10.16
Granted (dollars per share) \| $ / shares	26.08
Forfeited (dollars per share) \| $ / shares	9.25
Exercised (dollars per share) \| $ / shares	18.31
Expired (dollars per share) \| $ / shares	24.45
Outstanding, ending balance (dollars per share) \| $ / shares	$ 11.94

Employee Equity-Based Compens50

Employee Equity-Based Compensation - Inputs to Calculate Estimated Fair Value of Options Awarded (Details) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected term (in years)	6 years 1 month 10 days	6 years 2 months 9 days
Volatility	68.00%	79.00%
Expected dividends	0.00%	0.00%
Risk free interest rates	2.69%	2.07%
Weighted average fair value (dollars per share)	$ 16.25	$ 16.84

Employee Equity-Based Compens51

Employee Equity-Based Compensation - Stock Option Supplemental Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Options Outstanding
Number of options (shares)	8,083,716	7,328,131
Weighted average remaining contractual term (in years)	6 years 4 months 6 days
Weighted average exercise price (dollars per share)	$ 11.94	$ 10.16
Weighted average fair value (dollars per share)	$ 8.46
Aggregate intrinsic value (in thousands)	$ 93,003
Options Exercisable
Number of options (shares)	5,667,598
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 3 months 26 days
Weighted average exercise price (dollars per share)	$ 7.86
Weighted average fair value (dollars per share)	$ 5.59
Aggregate intrinsic value (in thousands)	$ 86,184

Employee Equity-Based Compens52

Employee Equity-Based Compensation - Restricted Stock Activity (Details) - RSUs and RSAs	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Number of Shares
Beginning balance (shares) \| shares	24,150
Granted (shares) \| shares	0
Forfeited (shares) \| shares	0
Vested/Released (shares) \| shares	(8,050)
Ending balance (shares) \| shares	16,100
Weighted Average Grant Date Fair Value per Share
Beginning balance (dollars per share) \| $ / shares	$ 26.45
Granted (dollars per share) \| $ / shares	0
Forfeited (dollars per share) \| $ / shares	0
Vested/Released (dollars per share) \| $ / shares	26.45
Ending balance (dollars per share) \| $ / shares	$ 26.45

Employee Equity-Based Compens53

Employee Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 5,602	$ 3,215
Unrecognized equity-based compensation cost	24,300
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized equity-based compensation cost, restricted stock units	135
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	46	0
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	1,612	726
Sales, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	3,944	$ 2,489
Capitalized inventory
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	451
Property and equipment
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 81

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Provision from income taxes	$ 184	$ 0
Pre-tax loss	$ 20,628	$ 14,200

Commitments - Narrative (Detail

Commitments - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
Commitments - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 342	$ 293
Research and development
Product Liability Contingency [Line Items]
Clinical trial expense		$ 9

Commitments - Operating Lease O

Commitments - Operating Lease Obligations (Details) $ in Thousands	Mar. 31, 2018USD ($)
Year ending December 31:
2,018	$ 838
2,019	204
2,020	87
2,021	46
2,022	4
Thereafter	0
Total operating lease obligations	$ 1,179

Industry and Geographic Infor57

Industry and Geographic Information - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)segment	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)
Segment Reporting [Abstract]
Number of operating segments \| segment	1
Segment Reporting Information [Line Items]
Lease Income	$ 9	$ 1
Trade accounts receivable	$ 1,065		$ 1,946
Total revenue \| Geographic concentration \| Foreign
Segment Reporting Information [Line Items]
Risk concentration	26.00%	2.00%
Net accounts receivable \| Geographic concentration \| Foreign
Segment Reporting Information [Line Items]
Trade accounts receivable	$ 553		$ 1,000

Industry and Geographic Infor58

Industry and Geographic Information - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 801	$ 530
Products	796	528
Services	5	2
Net sales	801	530
Accelerate Pheno™ revenue
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	770	504
Other revenue
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	31	26
Domestic
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	595	518
Foreign
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 206	$ 12

Industry and Geographic Infor59

Industry and Geographic Information - Long-lived Assets by Geographic Territory (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Long-lived assets (excluding intangible assets)	$ 5,851	$ 4,890
Property and equipment \| Geographic concentration
Segment Reporting Information [Line Items]
Long-lived assets (excluding intangible assets)	5,851	4,890
Property and equipment \| Geographic concentration \| Domestic
Segment Reporting Information [Line Items]
Long-lived assets (excluding intangible assets)	4,494	3,779
Property and equipment \| Geographic concentration \| Foreign
Segment Reporting Information [Line Items]
Long-lived assets (excluding intangible assets)	$ 1,357	$ 1,111

Related Party Transaction (Deta

Related Party Transaction (Details)	Mar. 31, 2018USD ($)
Director \| Note holder
Related Party Transaction [Line Items]
Aggregate principal amount	$ 30,000,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	Apr. 06, 2018	Mar. 31, 2018
Subsequent Event [Line Items]
Over-allotment option, percent		15.00%
Over-allotment option		$ 22,500
Over-allotment option period		13 days
Subsequent event
Subsequent Event [Line Items]
Additional proceeds	$ 21,500
Long-term debt	14,600
Equity component	6,900
Debt issuance costs	645
Subsequent event \| Long-term debt
Subsequent Event [Line Items]
Debt issuance costs	439
Subsequent event \| Additional paid-in capital
Subsequent Event [Line Items]
Debt issuance costs	$ 206